BriaCell Enters Definitive Arrangement Agreement For The Spin Out Of BriaPro Therapeutics Corp.; 1 BriaCell Common Share And 1 Spinco Share For Each BriaCell Common Share That Was Issuable Upon Exercise Of The BriaCell Warrant
Portfolio Pulse from Happy Mohamed
BriaCell Therapeutics Corp. has entered into an arrangement agreement with BriaPro Therapeutics Corp. to spin out certain pre-clinical pipeline assets, including Bria-TILsRx™ and PKCδ inhibitors. BriaCell shareholders will receive one SpinCo share and one new BriaCell share for each BriaCell share held.
May 25, 2023 | 1:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BriaCell's spin-out of pre-clinical assets to BriaPro Therapeutics Corp. may create long-term value for shareholders, who will receive SpinCo and new BriaCell shares.
The spin-out of pre-clinical assets to BriaPro Therapeutics Corp. allows BriaCell to focus on its lead clinical candidate, Bria-IMT™, in advanced metastatic breast cancer. This move may create long-term value for shareholders, as they will receive shares in both BriaCell and SpinCo. The spin-out may also lead to increased focus and resources for the development of the spun-out assets, potentially resulting in positive outcomes for both companies.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100